In a small case series, an astonishing 57% of severely agitated patients given intramuscular ketamine in the prehospital setting were intubated in the ED.
We have previously expressed some hesitance about use of ketamine as a first-line choice for sedation in agitated patients (NEJM JW Emerg Med Apr 2017 and Am J Emerg Med 2017; 35:1000). In a prospective observational study, investigators assessed outcomes for a case series of 49 patients with severe agitation who received 5 mg/kg intramuscular (IM) ketamine for sedation in the prehospital setting.
Adequate sedation was achieved in a median time of 4.2 minutes and by 90% of patients. Of the 49 patients, 57% were intubated in the emergency department (ED), and of these, 36% were intubated by a single physician. Among intubated patients, the indication for intubation was “Airway Unprotected NOS” for 36%.
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals